Jae-Ouk Kim

Dr. Jae-Ouk Kim

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Virus Research
Verified
Journal Article
Open access
JGJunghyun Goo
Junghyun Goo
YJYuji Jeong
Yuji Jeong
YPYoung-Shin Park
Young-Shin Park
EYEunji Yang
Eunji Yang
DJDae-Im Jung
Dae-Im Jung
MSManki Song
Manki Song
Middle East Respiratory Syndrome coronavirus (MERS-CoV) causes severe pulmonary infection, with ∼35 % mortality. Spike glycoprotein (S) of MERS-CoV is a key target for vaccines and therapeutics because S mediates viral entry and membrane-fusion to host cells. Here, four different S subunit proteins, receptor-binding domain (RBD; 358-606 aa), S1 (1-751 aa), S2 (752-1296 aa), and SΔTM (1-1296 aa), were generated using the baculoviral system and immunized in mice to develop neutralizing antibodies. We developed 77 hybridomas and selected five neutralizing mAbs by immunization with SΔTM against MERS-CoV EMC/2012 strain S-pseudotyped lentivirus. However, all five monoclonal antibodies (mAb) did not neutralize the pseudotyped V534A mutation. Additionally, one mAb RBD-14F8 did not show neutralizing activity against pseudoviruses with amino acid substitution of L506 F or D509 G (England1 strain, EMC/2012 L506 F, and EMC/2012 D509 G), and RBD-43E4 mAb could not neutralize the pseudotyped I529 T mutation, while three other neutralizing mAbs showed broad neutralizing activity. This implies that the mutation in residue 506-509, 529, and 534 of S is critical to generate neutralization escape variants of MERS-CoV. Interestingly, all five neutralizing mAbs have binding affinity to RBD, although most mAbs generated by RBD did not have neutralizing activity. Additionally, chimeric antibodies of RBD-14F8 and RBD-43E4 with human Fc and light chain showed neutralizing effect against wild type MERS-CoV KOR/KNIH/002, similar to the original mouse mAbs. Thus, our mAbs can be utilized for the identification of specific mutations of MERS-CoV.

14 February 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EKEun Jin Kim
Eun Jin Kim
HYHyun Jin Yu
Hyun Jin Yu
JLJehee Lee
Jehee Lee
JKJae-Ouk Kim
Jae-Ouk Kim
SHSeung Hyun Han
Seung Hyun Han
DKDong Wook Kim
Dong Wook Kim
Significance: Vibrio cholerae O1, the causative agent of the disease cholera, has two biotypes: namely classical and El Tor. The disease is the principal manifestation of a potent toxin known as cholera toxin, produced by the bacteria. Generation of a toxin producing V. cholerae strain arises by infection of a toxin gene-carrying phage (CTX phage) that becomes integrated into its genome. Experimental evidence has shown the replication and transmission of the type-specific phage in the El Tor strains, but this has not been experimentally demonstrated in the classical strains and the exact mechanism was not known. This study provides laboratory evidence that illustrates the genesis of toxigenic classical biotype strains.

31 October 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
MKMin Jung Kim
Min Jung Kim
YMYoung-Hye Moon
Young-Hye Moon
HKHeejoo Kim
Heejoo Kim
SRSemi Rho
Semi Rho
Young Kee ShinYoung Kee Shin
Young Kee Shin
JKJae-Ouk Kim
Jae-Ouk Kim
Shigella is a highly prevalent bacterium causing acute diarrhea and dysentery in developing countries. Shigella infections are treated with antibiotics but Shigellae are increasingly resistant to these drugs. Vaccination can be a countermeasure against emerging antibiotic-resistant shigellosis. Because of the structural variability in Shigellae O-antigen polysaccharides (Oag), cross-protective Shigella vaccines cannot be derived from single serotype-specific Oag. We created an attenuated Shigella flexneri 2a strain with one rather than multiple Oag units by disrupting the Oag polymerase gene (Δwzy), which broadened protective immunogenicity by exposing conserved surface proteins. Inactivated Δwzy mutant cells combined with Escherichia coli double mutant LT(R192G/L211A) as adjuvant, induced potent antibody responses to outer membrane protein PSSP-1, and type III secretion system proteins IpaB and IpaC. Intranasal immunization with the vaccine preparation elicited cross-protective immunity against S. flexneri 2a, S. flexneri 3a, S. flexneri 6, and Shigella sonnei in a mouse pneumonia model. Thus, S. flexneri 2a Δwzy represents a promising candidate strain for a universal Shigella vaccine.

4 February 2015 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
JKJae-Ouk Kim
Jae-Ouk Kim
SRSemi Rho
Semi Rho
SKSu Hee Kim
Su Hee Kim
HKHeejoo Kim
Heejoo Kim
HSHyo Jin Song
Hyo Jin Song
DKDong Wook Kim
Dong Wook Kim
In developing countries,Shigellais a primary cause of diarrhea in infants and young children. Although antibiotic therapy is an effective treatment for shigellosis, therapeutic options are narrowing due to the emergence of antibiotic resistance. Thus, preventive vaccination could become the most efficacious approach for controlling shigellosis. We have identified several conserved protein antigens that are shared by multipleShigellaserotypes and species. Among these, one antigen induced cross-protection against experimental shigellosis, and we have named it pan-Shigellasurface protein 1 (PSSP-1). PSSP-1-induced protection requires a mucosal administration route and coadministration of an adjuvant. When PSSP-1 was administered intranasally, it induced cross-protection againstShigella flexneriserotypes 2a, 5a, and 6,Shigella boydii,Shigella sonnei, andShigella dysenteriaeserotype 1. Intradermally administered PSSP-1 induced strong serum antibody responses but failed to induce protection in the mouse lung pneumonia model. In contrast, intranasal administration elicited efficient local and systemic antibody responses and production of interleukin 17A and gamma interferon. Interestingly, blood samples from patients with recent-onset shigellosis showed variable but significant mucosal antibody responses to other conservedShigellaprotein antigens but not to PSSP-1. We suggest that PSSP-1 is a promising antigen for a broadly protective vaccine againstShigella.

1 October 2017 in Immunology Letters
Verified
Journal Article
Closed access
SRSemi Rho
Semi Rho
HKHeejoo Kim
Heejoo Kim
SSSeung Hyun Shim
Seung Hyun Shim
SLSeung Young Lee
Seung Young Lee
MKMin Jung Kim
Min Jung Kim
JKJae-Ouk Kim
Jae-Ouk Kim

7 November 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Jonathan LovellJonathan Lovell
Jonathan Lovell
KMKazutoyo Miura
Kazutoyo Miura
YBYeong Ok Baik
Yeong Ok Baik
CLChankyu Lee
Chankyu Lee
JLJeong-Yoon Lee
Jeong-Yoon Lee
JCJung-Hyun Choi
Jung-Hyun Choi
EuCorVac-19 (ECV-19), an adjuvanted liposome-displayed receptor binding domain (RBD) COVID-19 vaccine, previously reported interim Phase 2 trial results showing induction of neutralizing antibodies 3 weeks after prime-boost immunization. The objective of this study was to determine the longer-term antibody response of the vaccine. To assess immunogenicity 6 and 12 months after vaccination, participants in the Phase 2 trial (NCT04783311) were excluded if they: 1) withdrew, 2) reported COVID-19 infection or additional vaccination, or 3) exhibited increasing Spike (S) antibodies (representing possible non-reported infection). Following exclusions, of the 197 initial subjects, anti-S IgG antibodies and neutralizing antibodies were further assessed in 124 subjects at the 6-month timepoint, and 36 subjects at the 12-month timepoint. Median anti-S antibody half-life was 52 days (interquartile range [IQR]:42-70), in the "early" period from 3 weeks to 6 months, and 130 days (IQR:97-169) in the "late" period from 6 to 12 months. There was a negative correlation between initial antibody titer and half-life. Anti-S and neutralizing antibody responses were correlated. Neutralizing antibody responses showed longer half-lives; the early period had a median half-life of 120 days (IQR:81-207), and the late period had a median half-life of 214 days (IQR:140-550). These data establish antibody durability of ECV-19, using a framework to analyze COVID-19 vaccine-induced antibodies during periods of high infection.